Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-08-30
DOI
10.3389/fimmu.2017.01010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results
- (2017) M. Bagot et al. HEMATOLOGICAL ONCOLOGY
- Expression of CD164 on Malignant T cells in Sézary Syndrome
- (2016) E Guenova et al. ACTA DERMATO-VENEREOLOGICA
- KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma
- (2016) M. Battistella et al. BRITISH JOURNAL OF DERMATOLOGY
- Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides
- (2016) Charlotte Hurabielle et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients
- (2016) Stephanie E. Boonk et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient
- (2015) T Honda et al. ACTA DERMATO-VENEREOLOGICA
- Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers
- (2015) Charlotte FM Hughes et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
- (2015) M. Duvic et al. BLOOD
- Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 9
- (2015) C.D. Klemke et al. BRITISH JOURNAL OF DERMATOLOGY
- The evolution of natural killer cell receptors
- (2015) Paola Carrillo-Bustamante et al. IMMUNOGENETICS
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
- (2015) Youn H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
- (2015) Madeleine Duvic et al. JOURNAL OF CLINICAL ONCOLOGY
- KIR3DL2/CpG ODN Interaction Mediates Sézary Syndrome Malignant T Cell Apoptosis
- (2015) Bouchra Ghazi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CD158k Is a Reliable Marker for Diagnosis of Sézary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells
- (2015) Hélène Moins-Teisserenc et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies
- (2015) Hélène Sicard et al. OncoImmunology
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- KIR3DL2 is a coinhibitory receptor on Sezary syndrome malignant T cells that promotes resistance to activation-induced cell death
- (2014) N. Thonnart et al. BLOOD
- Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas
- (2014) A. de Masson et al. BRITISH JOURNAL OF DERMATOLOGY
- IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma
- (2014) A. Marie-Cardine et al. CANCER RESEARCH
- Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
- (2014) X. Ni et al. CLINICAL CANCER RESEARCH
- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- (2014) Michinori Ogura et al. JOURNAL OF CLINICAL ONCOLOGY
- Umbilical Cord Blood T Cells Express Multiple Natural Cytotoxicity Receptors after IL-15 Stimulation, but Only NKp30 Is Functional
- (2014) Q. Tang et al. JOURNAL OF IMMUNOLOGY
- Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma
- (2014) Sean H. Lim et al. JOURNAL OF IMMUNOLOGY
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
- (2014) Sarah I. Jawed et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry
- (2013) A. Horowitz et al. Science Translational Medicine
- Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays
- (2012) Josée Golay et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides
- (2012) Nicolas Ortonne et al. EXPERIMENTAL DERMATOLOGY
- Extravillous trophoblast and decidual natural killer cells: a remodelling partnership
- (2012) A. E. Wallace et al. HUMAN REPRODUCTION UPDATE
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
- (2011) Y. H. Kim et al. BLOOD
- Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis
- (2011) P. Bowness et al. JOURNAL OF IMMUNOLOGY
- Peripheral blood findings in erythrodermic patients: Importance for the differential diagnosis of S?zary syndrome
- (2011) Arielle R. Nagler et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2
- (2010) S. Sivori et al. BLOOD
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
- (2010) Kazuhito Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression and Function of the Natural Cytotoxicity Receptor NKp46 on Circulating Malignant CD4+ T Lymphocytes of Sézary Syndrome Patients
- (2010) Armand Bensussan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- (2010) Youn H. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Peptide antagonism as a mechanism for NK cell activation
- (2010) L. Fadda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NK cells and surveillance in humans
- (2010) Christian Schmitt et al. REPRODUCTIVE BIOMEDICINE ONLINE
- Absolute CD3+âCD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome
- (2009) J.-D. Bouaziz et al. BRITISH JOURNAL OF DERMATOLOGY
- Lack of T-Cell Receptor-Induced Signaling Is Crucial for CD95 Ligand Up-regulation and Protects Cutaneous T-Cell Lymphoma Cells from Activation-Induced Cell Death
- (2009) C.-D. Klemke et al. CANCER RESEARCH
- A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
- (2008) Arturo Molina Annual Review of Medicine
- The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells
- (2008) P. Brodin et al. BLOOD
- The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers
- (2008) C.-D. Klemke et al. BRITISH JOURNAL OF DERMATOLOGY
- Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC
- (2008) E. Marcenaro et al. INTERNATIONAL IMMUNOLOGY
- The Usefulness of CD26 in Flow Cytometric Analysis of Peripheral Blood in Sézary Syndrome
- (2007) Katalin Kelemen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry
- (2007) David W. Bahler et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of Sézary Syndrome
- (2007) Nicolas Ortonne et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now